Utility of Comprehensive Serum Glycopeptide Spectra Analysis (CSGSA) for the Detection of Early Stage Epithelial Ovarian Cancer.

cancer antigen 125 comprehensive serum glycopeptide spectra analysis epithelial ovarian cancer human epididymis protein 4 orthogonal partial least-squares discriminant analysis screening

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
21 Aug 2020
Historique:
received: 06 07 2020
revised: 12 08 2020
accepted: 18 08 2020
entrez: 23 8 2020
pubmed: 23 8 2020
medline: 23 8 2020
Statut: epublish

Résumé

Comprehensive serum glycopeptide spectra analysis (CSGSA) evaluates >10,000 serum glycopeptides and identifies unique glycopeptide peaks and patterns via supervised orthogonal partial least-squares discriminant modeling. CSGSA was more accurate than cancer antigen 125 (CA125) or human epididymis protein 4 (HE4) for detecting early stage epithelial ovarian cancer. Combined CSGSA, CA125, and HE4 had improved diagnostic performance. Thus, CSGSA may be a useful screening tool for detecting early stage epithelial ovarian cancer.

Identifiants

pubmed: 32825727
pii: cancers12092374
doi: 10.3390/cancers12092374
pmc: PMC7563232
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 17H04340;18K09274; and 18K09300
Organisme : AMED
ID : 20lm0203004j0003
Organisme : Ensign Endowment for Gynecologic Cancer Research
ID : -

Références

Obstet Gynecol. 2011 Jun;117(6):1289-97
pubmed: 21606739
JAMA Oncol. 2020 Jul 1;6(7):1110-1113
pubmed: 32525512
Curr Metabolomics. 2016;4(2):97-103
pubmed: 27547730
Gynecol Oncol. 2015 Dec;139(3):520-8
pubmed: 26477941
Anal Bioanal Chem. 2004 Oct;380(3):419-29
pubmed: 15448969
Arch Gynecol Obstet. 2018 Mar;297(3):749-756
pubmed: 29340789
J Proteome Res. 2016 Sep 2;15(9):2935-44
pubmed: 27354006
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Cancers (Basel). 2019 Apr 27;11(5):
pubmed: 31035594

Auteurs

Koji Matsuo (K)

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA 90033, USA.
Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA.

Kazuhiro Tanabe (K)

Medical Solution Promotion Department, LSI Medience Corporation, Tokyo 1748555, Japan.

Masaru Hayashi (M)

Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa 2591193, Japan.

Masae Ikeda (M)

Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa 2591193, Japan.

Miwa Yasaka (M)

Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa 2591193, Japan.

Hiroko Machida (H)

Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa 2591193, Japan.

Masako Shida (M)

Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa 2591193, Japan.

Kenji Sato (K)

Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa 2591193, Japan.

Hiroshi Yoshida (H)

Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa 2591193, Japan.

Takeshi Hirasawa (T)

Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa 2591193, Japan.

Tadashi Imanishi (T)

Department of Molecular Life Science, Division of Basic Medical Science and Molecular Medicine, Tokai University School of Medicine, Kanagawa 2591193, Japan.

Mikio Mikami (M)

Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa 2591193, Japan.

Classifications MeSH